Fortrea Holdings Inc. Stock

Equities

FTRE

US34965K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
25.55 USD -0.58% Intraday chart for Fortrea Holdings Inc. -5.05% -26.79%
Sales 2024 * 2.8B Sales 2025 * 2.93B Capitalization 2.28B
Net income 2024 * -57M Net income 2025 * 59M EV / Sales 2024 * 1.38 x
Net Debt 2024 * 1.57B Net Debt 2025 * 1.42B EV / Sales 2025 * 1.26 x
P/E ratio 2024 *
-27.8 x
P/E ratio 2025 *
35.3 x
Employees 16,000
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.58%
1 week-5.05%
Current month-30.17%
1 month-29.71%
3 months-31.65%
6 months-23.85%
Current year-26.79%
More quotes
1 week
25.10
Extreme 25.1
26.88
1 month
25.10
Extreme 25.1
38.04
Current year
25.10
Extreme 25.1
41.02
1 year
24.93
Extreme 24.925
41.02
3 years
24.93
Extreme 24.925
41.02
5 years
24.93
Extreme 24.925
41.02
10 years
24.93
Extreme 24.925
41.02
More quotes
Date Price Change Volume
24-05-24 25.55 -0.58% 1,483,410
24-05-23 25.7 -2.58% 2,067,543
24-05-22 26.38 +0.27% 1,411,065
24-05-21 26.31 -2.23% 1,549,408

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT

More quotes
Fortrea Holdings Inc. is a global contract research organization (CRO). The Company is providing clinical development, patient access solutions and consulting to the life sciences industry. The Company provides phase I through IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. The Company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment offers solutions to the market that include clinical pharmacology and comprehensive clinical development capabilities. Its Enabling Services segment provides patient access and technology solutions that can be deployed as a standalone offering or across its global solutions depending on the scope of its customers’ needs. The Company offers its customers with clinical trial solutions through three delivery models: Full Service, Functional Service Provider, and Hybrid.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
25.55 USD
Average target price
33.71 USD
Spread / Average Target
+31.95%
Consensus